Ligand-based CAR-T cell: Different strategies to drive T cells in future new treatments

Chimeric antigen receptor (CAR)-based therapies are presented as innovative treatments for multiple malignancies. Despite their clinical success, there is scientific evidence of the limitations of these therapies mainly due to immunogenicity issues, toxicities associated with the infusion of the pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramírez-Chacón, Alejandro, Betriu-Méndez, Sergi, Bartoló-Ibars, Ariadna, González, Azucena, Martí, Mercè, Juan, Manel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511026/
https://www.ncbi.nlm.nih.gov/pubmed/36172370
http://dx.doi.org/10.3389/fimmu.2022.932559

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511026/
https://www.ncbi.nlm.nih.gov/pubmed/36172370
http://dx.doi.org/10.3389/fimmu.2022.932559

Ejemplares similares